Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer

Nepal, Sat Prasad; Nakasato, Tatsuhiko; Fukushima, Takashi; Ogawa, Yoshio; Nakagami, Yoshihiro; Shichijo, Takeshi; Murata, Jun; Maeda, Yukihide; Oshinomi, Kazuhiko; Unoki, Tsutomu; Noguchi, Tetsuo; Inoue, Tatsuki; Kato, Ryosuke; Amano, Sadao; Mizunuma, Moyuru; Kurokawa, Masahiro; Tsunokawa, Yoshiki; Yasuda, Sou

doi:10.1016/j.ajur.2022.02.007

Asian Journal of Urology

2023

DOI: 10.1016/j.ajur.2022.02.007

|View full text |Cite

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer

Sat Prasad Nepal

Tatsuhiko Nakasato

Takashi Fukushima

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Predictive value of neutrophil-to-lymphocyte ratio for clinically significant prostate cancer

Ren Jhuang,

Hong,

Huang

et al. 2024

Urological Science

View full text Add to dashboard Cite

Purpose: The neutrophil-to-lymphocyte ratio (NLR), one of the inflammatory markers, can be calculated simply from peripheral blood samples. In this study, the role of NLR in predicting significant prostate cancer (sPC) before prostate biopsy was investigated. Materials and methods: Patients who underwent prostate biopsy between 2017 and 2022 at the National Taiwan University Hospital were enrolled prospectively. NLR was calculated before the biopsy. sPC was defined as an unfavorable-intermediate or higher risk of the National Comprehensive Cancer Network risk classification. Results: Among 484 enrolled patients, 164 sPC (33.9%) and 320 benign/insignificant prostate cancer (isPC; 66.1%) patients were diagnosed. The sPC group was older and had a higher prostate-specific antigen (PSA), smaller prostate volume, higher PSA density, more advanced clinical T stage, and more family history of prostate cancer than the benign/isPC group. There was no difference in neutrophil count (P = 0.929), lymphocyte count (P = 0.927), or NLR (P = 0.931) between groups. NLR failed to predict sPC in univariable (odds ratio, 1.02; 95% confidence interval [CI], 0.93–1.12; P = 0.7) and multivariable (odds ratio, 0.94; 95% CI, 0.79–1.12; P = 0.506) logistic regression models, respectively. The area under the curve of the receiver operating characteristic curve in the model consisted of age, PSA, prostate volume, T stage, and family history of prostate cancer was 0.882 (95% CI, 0.849–0.914). There was no statistical difference when the model included NLR (P = 0.625). Conclusion: NLR did not differ between sPC and benign/isPC groups. NLR cannot predict sPC successfully before prostate biopsy.

show abstract

Predictive value of neutrophil-to-lymphocyte ratio for clinically significant prostate cancer

Ren Jhuang,

Hong,

Huang

et al. 2024

Urological Science

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer

Cited by 1 publication

References 35 publications

Predictive value of neutrophil-to-lymphocyte ratio for clinically significant prostate cancer

Predictive value of neutrophil-to-lymphocyte ratio for clinically significant prostate cancer

Contact Info

Product

Resources

About